Comparing proton and photon therapy for esophageal cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The PROTECT trial aims to evaluate whether proton therapy can reduce treatment-related pulmonary complications in patients with operable esophageal cancer compared to standard photon therapy. This international multicenter randomized phase III study will involve patients receiving either neoadjuvant chemotherapy followed by proton therapy or photon therapy. Patients will be randomly assigned to one of the two treatment arms, with the study ensuring allocation concealment through a centralized online randomization system. The trial will also standardize chemotherapy regimens across all participating centers to maintain consistency in treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with histologically verified squamous cell carcinoma or adenocarcinoma (including signet cell carcinoma and large cell carcinoma, not further specified) of the esophagus (E) or gastro-esophageal junction (GEJ).

  * FDG PET/CT performed.
  * Tumor stage according to TNM (8th edition): cT1-4a and/or cN+, cM0.
  * Age ≥18 years.
  * Performance status WHO ≤2.
  * Adequate laboratory findings: hematological: hemoglobin \> 90 g/L, absolute neutrophil count (ANC) ≥ 1,5 x 109/L, platelets ≥ 75 x 109/L hepatic: bilirubin ≤ 1.5 x upper limit of normal (ULN), ALAT ≤ 3 x ULN renal: creatinine ≤ 1.5 x ULN, GFR (may be calculated) \> 30 ml/min
  * MDT decision on suitability to undergo curatively intended nCXT or nCPT followed by surgery.
  * Planned transthoracic esophagectomy or gastrectomy being open, minimally invasive of combination of both.
  * Ability to adhere to procedures for study and follow-up.
  * Patients with low risk cancers with a life expectancy above 5 years (e.g. low risk prostate cancer) are allowed in the study. Adequately treated diagnoses such as cervix uteri carcinoma in situ, in situ urothelial carcinoma or localized non-melanoma skin cancer are allowed, regardless of time of diagnosis.
  * Patients of childbearing potential: pregnancy prevention according to the standards of each country. Patients of childbearing potential must present a negative pregnancy test. Patients and their partners must use effective contraception. Patients of childbearing potential included in the study must use oral contraceptives, intrauterine devices, depot injection of progestin subdermal implantation, a hormonal vaginal ring, or transdermal patch during the study treatment and one month after.

Exclusion Criteria:

Patients who meet one or more of the following exclusion criteria cannot be included in the study:

* Prior thoracic XT or PT, chemotherapy or surgical resection in the esophageal/gastric region (previous EMR or ESD is allowed).
* Tumor \< 3 cm from oropharyngeal sphincter.
* Planned transhiatal resection
* Patients with other previous malignancies are excluded unless a complete remission or complete resection was achieved at least 5 years prior to study entry.
* Any unstable systemic disease (including clinically significant lung and cardiovascular disease, unstable angina, New York Heart Association (NYHA) grade III-IV congestive heart, severe hepatic, renal or metabolic disease or active inflammatory bowel disease).
* Symptomatic peripheral neuropathy greater than grade 1 (scored according to CTCAE v5.0).
* Any other serious or uncontrolled illness, which, in the opinion of the investigator, makes it undesirable for the patient to enter the trial.
* Unable to understand and digest study patient information or comply with study treatment and safety instructions.
* Gastro-esophageal stent within the irradiated volume.

Where it's running

• Catholic University of Leuven
  Leuven, Belgium Recruiting
• Aarhus University Hospital (AUH)
  Aarhus, Denmark Recruiting
• Technische Universität Dresden (TUD)
  Dresden, Germany Recruiting
• San Raffaele Hospital
  Milan, Italy Recruiting
• Centro Nazionale di Adroterapia Oncologica (CNAO)
  Pavia, Italy Recruiting
• Azienda Provinciale Per I Servizi Sanitari (APSS)
  Trento, Italy Recruiting

Study contacts

• Study coordinator: Dorte Winter
• Email: dorte.skriver.winther@auh.rm.dk
• Phone: +45 78456442

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Analysis of outcomes and side effects in patients receiving radiation therapy

  This study looks at the results and side effects of radiation therapy in patients at Winterthur Cantonal Hospital to see how treatment can be improved for future patients.

  Recruiting Kantonsspital Winterthur KSW · Winterthur, Canton of Zurich · NCT05192876

• Using MRI scans to monitor cancer treatment response during radiation therapy

  This study is testing if regular MRI scans can help doctors see how well radiation therapy is working for patients with advanced cancers like glioblastoma and esophageal cancer.

  Recruiting at 2 sites Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT04188535

• PF-08098488 in adults with advanced solid tumors

  This study tests PF-08098488 in adults whose cancer has progressed or returned after prior treatment.

  Recruiting at 4 sites Phase 1 Pfizer · Grand Rapids, Michigan and 3 other locations · NCT07903415

• Primary tumor removal with targeted lymph node removal plus radiation for biliary tract cancer with lymph node spread

  This phase II study tests whether removing the main tumor and select nearby lymph nodes, followed by postoperative radiation, helps patients with biliary tract cancer and lymph node metastases.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07893392

• Modular Robot-Assisted Esophagectomy vs. Conventional Minimally Invasive Esophagectomy for Esophageal Cancer

  This trial tests whether modular robotic-assisted esophagectomy using the Carina platform works better than conventional 3D thoracoscopic esophagectomy for people with resectable esophageal cancer.

  Recruiting Phase 3 Ruijin Hospital · Shanghai · NCT07888140

• Protoacoustic Imaging to See Radiation Delivery in Proton Therapy

  This study tests radioacoustic imaging with ultrasound to help doctors see where proton therapy is delivering radiation for liver and prostate cancer patients.

  Recruiting University of Oklahoma · Oklahoma City, Oklahoma · NCT07832617

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.